Cargando…
Impact of Muscarinic M(3) Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study
BACKGROUND: M(3) muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. OBJECTIVE: Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M(3) muscarinic receptor antagonis...
Autores principales: | Tran, Yen-Hao, Schuiling-Veninga, Catharina C. M., Bergman, Jorieke E. H., Groen, Henk, Wilffert, Bob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488147/ https://www.ncbi.nlm.nih.gov/pubmed/28527131 http://dx.doi.org/10.1007/s40263-017-0436-x |
Ejemplares similares
-
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key?
por: Daud, Aizati N. A., et al.
Publicado: (2016) -
Poor guideline adherence in the initiation of antidepressant treatment in children and adolescents in the Netherlands: choice of antidepressant and dose
por: de Vries, Ymkje Anna, et al.
Publicado: (2016) -
Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020) -
Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: The PharmLines initiative
por: Sediq, Rahmat, et al.
Publicado: (2018) -
Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting
por: Wang, Yuanyuan, et al.
Publicado: (2021)